首页 | 本学科首页   官方微博 | 高级检索  
检索        


Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor,in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept,open-label,phase 2a study
Authors:Alejandro Llanos-Cuentas  Martin Casapia  Raúl Chuquiyauri  Juan-Carlos Hinojosa  Nicola Kerr  Maria Rosario  Stephen Toovey  Robert H Arch  Margaret A Phillips  Felix D Rozenberg  Jade Bath  Caroline L Ng  Annie N Cowell  Elizabeth A Winzeler  David A Fidock  Mark Baker  Jörg J Möhrle  Rob Hooft van Huijsduijnen  Stephan Duparc
Institution:1. Universidad Peruana Cayetano Heredia, Lima, Peru;2. Asociación Civil Selva Amazónica, Iquitos, Peru;3. Medicines for Malaria Venture, Geneva, Switzerland;4. Takeda Development Center Americas Inc, Cambridge, MA, USA;5. Department of Biochemistry, University of Texas Southwestern Medical Centre, Dallas, TX, USA;6. Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, USA;7. Division of Infectious Diseases, Department of Medicine, Columbia University Medical Center, New York, NY, USA;8. School of Medicine, University of California San Diego, La Jolla, CA, USA;9. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA;10. GlaxoSmithKline Consumer Healthcare Switzerland AG, Rotkreuz, Switzerland;11. GeNeuro SA, Geneva, Switzerland
Abstract:
Keywords:Correspondence to: Dr Stephan Duparc  Medicines for Malaria Venture  1215 Geneva 15  Switzerland
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号